Tonix Pharmaceuticals (TNXP) Announces Presentation of Additional TNX-102 SL Phase 2 Data in Fibromyalgia
Tweet Send to a Friend
Tonix Pharmaceuticals (NASDAQ: TNXP) presented additional data from its Phase 2b BESTFIT clinical study further supporting TNX-102 SL (cyclobenzaprine HCl ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
